Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.